精炼食用油对神经退行性疾病的影响
Fataneh Hashempour-Baltork1, Parastou Farshi2, Adel Mirza Alizadeh3
1Halal Research Center of IRI, Iran Food and Drug Administration, Ministry of Health and Medical Education, Tehran, Iran.
Advanced pharmaceutical bulletin
|August 30, 2023
概括
饮食中的植物油可能会影响神经退行性疾病的进展. 富含有益的小成分的原油可能提供预防性策略来对抗这些令人衰弱的神经疾病.
科学领域:
- 营养科学 营养科学
- 神经学 神经学
- 生物化学 生物化学
背景情况:
- 神经退行性疾病是一个重大的全球健康挑战,通常以不可治愈的疾病和有限的治疗选择为特征.
- 老龄化是主要的风险因素,但与饮食相关的因素越来越被认为对疾病发病的关键.
- 植物油是饮食的主食,含有三糖醇和影响健康的重要微量成分.
研究的目的:
- 审查精炼植物油与未精炼植物油消费对神经退行性疾病的影响.
- 评估植物油作为潜在的预防或治疗策略.
- 为了突出关注植物油炼油过程中营养损失的问题.
主要方法:
- 文献综述侧重于研究植物油消费和神经退行性疾病的研究.
- 精炼和未精炼植物油的生物化学成分的分析.
- 评估小组件在神经健康中的作用.
主要成果:
- 由于化学处理和高温,炼油过程可能导致植物油中有益的次要成分丧失.
- 这些丢失的成分可能在身体和神经健康中发挥作用.
- 精炼油与未精炼油对疾病进展的影响差异需要进一步研究.
结论:
- 不精炼的植物油保留了它们的自然小成分,可能有潜力预防或减缓神经退行性疾病.
- 植物油的加工需要仔细考虑,以保持促进健康的成分.
- 需要进一步的研究来阐明植物油影响神经退行的具体机制.
相关概念视频
Alzheimer's Disease: Overview
517
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
517
Parkinson's Disease: Overview
593
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
593
Alzheimer's Disease: Treatment
212
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
212
Disorders of the Nervous Tissue
1.4K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.4K
Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
Role of Neurotransmitters in Memory
623
Neurotransmitters are integral to the brain's communication system, enabling neurons to transmit signals across synapses. This chemical exchange underpins various cognitive functions, including memory processes. The role of neurotransmitters in memory is multifaceted, influencing the encoding, consolidation, and retrieval of memories through their action on different neural circuits.
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
Glutamate and Synaptic Plasticity
Glutamate, the brain's main excitatory neurotransmitter, is...
623


